Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefan Heitmeier is active.

Publication


Featured researches published by Stefan Heitmeier.


Journal of Thrombosis and Haemostasis | 2017

Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study

Reinhold Kreutz; Pontus B. Persson; Dagmar Kubitza; Kirstin Thelen; Stefan Heitmeier; Stephan Schwers; Michael Becka; Melanie Hemmrich

Essentials In this crossover study the anticoagulant effects of rivaroxaban and apixaban were compared. Healthy volunteers received rivaroxaban 20 mg once daily or apixaban 5 mg twice daily. Rivaroxaban was associated with more prolonged inhibition of thrombin generation than apixaban. Rivaroxaban induced a clear prolongation of prothrombin time and activated partial thromboplastin time.


Journal of the American College of Cardiology | 2018

INHIBITORY MECHANISMS OF VERY LOW DOSE RIVAROXABAN IN NON-ST-ELEVATION MYOCARDIAL INFARCTION

Tobias Geisler; Patrick Muenzer; Nada Alnaggar; Sascha Geue; Roland Tegtmeyer; Dominik Rath; Michal Droppa; Peter Seizer; Stefan Heitmeier; Johan W. M. Heemskerk; Lisa K. Jennings; Robert F. Storey; Dominick J. Angiolillo; Bianca Rocca; Henri M.H. Spronk; Hugo ten Cate; Meinrad Gawaz; Oliver Borst

Very low dose (VLD) factor Xa (FXA) inhibition in combination with acetylsalicylic acid (ASA) and clopidogrel is associated with improved outcomes in patients with acute coronary syndrome (ACS) with a tolerable bleeding risk profile. To date there are no data documenting platelet inhibition and


Archive | 2008

Substituted imidazopyrimidines and triazolopyrimidines

Stephan Siegel; Andreas Wilmen; Susanne Röhrig; Niels Svenstrup; Mark Jean Gnoth; Stefan Heitmeier; Ulrich Rester; Dmitry Zubov; Jochen Strayle; Michael Sperzel


Archive | 2008

IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE

Stephan Siegel; Andreas Wilmen; Susanne Röhrig; Niels Svenstrup; Mark Jean Gnoth; Stefan Heitmeier; Ulrich Rester; Adrian Tersteegen; Michael Gerisch


Archive | 2010

Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof

Thomas Lampe; Michael Hahn; Johannes-Peter Stasch; Karl-Heinz Schlemmer; Frank Wunder; Stefan Heitmeier; Nils Griebenow; Sheikh Sherif El; Volkhart Min-Jian Li; Eva-Maria Becker; Friederike Stoll; Andreas Knorr


Archive | 2008

Substituted oxazolidinones and their use

Swen Allerheiligen; Marcus Bauser; Hartmut Schirok; Ulrich Rester; Stefan Heitmeier; Christoph Gerdes; Georges Degenfeld; Elke Dittrich-Wengenroth; Uwe Saatmann; Julia Straβburger; Klaus Münter; Mark Jean Gnoth; Dieter Lang


Archive | 2007

Method for detecting pyrophosphate by means of bioluminescence detection

Nils Burkhardt; Stefan Heitmeier


Archive | 2009

Aliphatically substituted pyrazolopyridines, and the use thereof

Hartmut Schirok; Nils Griebenow; Chantal Fürstner; Joachim Mittendorf; Johannes-Peter Stasch; Frank Wunder; Stefan Heitmeier


Archive | 2008

Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation

Swen Allerheiligen; Marcus Bauser; Dirk Heimbach; Stefan Heitmeier; Mark Jean Gnoth; Christoph Gerdes; Georges Degenfeld; Susanne Röhrig; Ulrich Rester; Elke Dittrich-Wengenroth; Uwe Saatmann; Adrian Tersteegen


Blood Advances | 2018

Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

Oliver Borst; Patrick Münzer; Nada Alnaggar; Sascha Geue; Roland Tegtmeyer; Dominik Rath; Michal Droppa; Peter Seizer; Stefan Heitmeier; Johan W. M. Heemskerk; Lisa K. Jennings; Robert F. Storey; Dominick J. Angiolillo; Bianca Rocca; Henri M.H. Spronk; Hugo ten Cate; Meinrad Gawaz; Tobias Geisler

Collaboration


Dive into the Stefan Heitmeier's collaboration.

Researchain Logo
Decentralizing Knowledge